AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Salmeterol is commonly prescribed as part of combination therapy for asthma, especially in cases where symptoms are not adequately controlled with other medications such as inhaled corticosteroids alone. It helps to prevent asthma symptoms such as wheezing, shortness of breath, chest tightness, and coughing. Salmeterol is not meant for the relief of acute asthma attacks but rather for long-term maintenance treatment.
Chronic Obstructive Pulmonary Disease (COPD): Salmeterol is also used in the treatment of COPD, including chronic bronchitis and emphysema. It helps to improve airflow in the lungs, reduce exacerbations, and alleviate symptoms such as shortness of breath and coughing. Like in asthma, salmeterol is used as part of combination therapy in COPD management.
Exercise-Induced Bronchoconstriction (EIB): Salmeterol can be used to prevent exercise-induced bronchoconstriction, a condition where physical activity triggers narrowing of the airways leading to symptoms like wheezing and shortness of breath. When taken before exercise, salmeterol helps to keep the airways open, thereby reducing the risk of EIB.
Prevention of Nocturnal Asthma Symptoms: Salmeterol is sometimes prescribed to prevent nocturnal asthma symptoms. By providing long-acting bronchodilation throughout the night, it can help improve sleep quality and reduce nighttime awakenings due to asthma symptoms.
Maintenance Therapy: Salmeterol is typically used as maintenance therapy, meaning it is taken regularly over an extended period to control and prevent symptoms rather than for immediate relief. It is usually prescribed in combination with an inhaled corticosteroid (ICS) for optimal asthma or COPD management.
Reduction of Airway Inflammation: While salmeterol primarily acts as a bronchodilator, it may also exert anti-inflammatory effects over time. By reducing airway inflammation, salmeterol helps to prevent exacerbations and improve lung function in individuals with asthma and COPD.
Symptom Control: By providing sustained bronchodilation for up to 12 hours after inhalation, salmeterol helps individuals with asthma and COPD maintain better control over their symptoms, leading to improved quality of life and reduced reliance on rescue medications.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.1 | -0.1 | |
ADHD | 2.5 | 2.5 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.3 | 0.67 |
Allergic Rhinitis (Hay Fever) | 1.3 | 0.4 | 2.25 |
Allergies | 2.6 | 1.1 | 1.36 |
Allergy to milk products | 0.7 | 0.6 | 0.17 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 2.3 | 4.5 | -0.96 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 1.2 | 0.67 |
Ankylosing spondylitis | 2 | 1 | 1 |
Anorexia Nervosa | 0.3 | 1 | -2.33 |
Antiphospholipid syndrome (APS) | 1.4 | 0.2 | 6 |
Asthma | 0.1 | 1.7 | -16 |
Atherosclerosis | 0.6 | 1.6 | -1.67 |
Atrial fibrillation | 1.5 | 1.2 | 0.25 |
Autism | 5.9 | 4.7 | 0.26 |
Barrett esophagus cancer | 0.4 | 0.1 | 3 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.9 | 0.5 | 0.8 |
Brain Trauma | 0.4 | 0.6 | -0.5 |
Carcinoma | 1.6 | 1.1 | 0.45 |
Celiac Disease | 0.9 | 1.7 | -0.89 |
Cerebral Palsy | 0.7 | 0.6 | 0.17 |
Chronic Fatigue Syndrome | 2.4 | 2.4 | 0 |
Chronic Kidney Disease | 2.3 | 1.5 | 0.53 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.3 | 1 |
Chronic Urticaria (Hives) | 0.9 | 1.4 | -0.56 |
Coagulation / Micro clot triggering bacteria | 1 | 0.4 | 1.5 |
Colorectal Cancer | 2.8 | 0.8 | 2.5 |
Constipation | 0.4 | 0.3 | 0.33 |
Coronary artery disease | 1.3 | 0.2 | 5.5 |
COVID-19 | 5.5 | 6.4 | -0.16 |
Crohn's Disease | 5.2 | 3.4 | 0.53 |
cystic fibrosis | 0.6 | 0.6 | 0 |
deep vein thrombosis | 0.6 | 0.4 | 0.5 |
Depression | 5.1 | 6.3 | -0.24 |
Dermatomyositis | 0.1 | 0.1 | 0 |
Eczema | 0.9 | 0.7 | 0.29 |
Endometriosis | 1.5 | 0.2 | 6.5 |
Eosinophilic Esophagitis | 0.2 | 0.2 | 0 |
Epilepsy | 1.9 | 2.6 | -0.37 |
Fibromyalgia | 1.7 | 1.3 | 0.31 |
Functional constipation / chronic idiopathic constipation | 2.6 | 2.6 | 0 |
gallstone disease (gsd) | 0.9 | 0.6 | 0.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.1 | 7 |
Generalized anxiety disorder | 1.4 | 0.5 | 1.8 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Graves' disease | 0.9 | 0.8 | 0.13 |
Halitosis | 0.6 | 0.1 | 5 |
Hashimoto's thyroiditis | 2.1 | 0.5 | 3.2 |
Hidradenitis Suppurativa | 0.4 | 0.2 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 0.8 | 1.13 |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.7 | -6 |
hyperglycemia | 0.2 | 1.7 | -7.5 |
Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.6 | 2.6 | -0.63 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0.9 | 0.9 | |
IgA nephropathy (IgAN) | 1.8 | -1.8 | |
Inflammatory Bowel Disease | 2.4 | 5.7 | -1.38 |
Insomnia | 0.3 | 0.6 | -1 |
Intelligence | 0.8 | 0.2 | 3 |
Intracranial aneurysms | 0.5 | 0.3 | 0.67 |
Irritable Bowel Syndrome | 2.7 | 2.7 | 0 |
Liver Cirrhosis | 2.4 | 1.6 | 0.5 |
Long COVID | 3.7 | 3.3 | 0.12 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.5 | 0.9 | -0.8 |
ME/CFS with IBS | 0.3 | 0.6 | -1 |
ME/CFS without IBS | 0.8 | 1.2 | -0.5 |
Menopause | 0.3 | 0.3 | |
Metabolic Syndrome | 4.8 | 4.9 | -0.02 |
Mood Disorders | 6.7 | 6.3 | 0.06 |
multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
Multiple Sclerosis | 2.4 | 3 | -0.25 |
Multiple system atrophy (MSA) | 1.7 | 0.1 | 16 |
Neuropathy (all types) | 0.4 | 0.2 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 2.3 | -1.56 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 5.7 | 3 | 0.9 |
obsessive-compulsive disorder | 3.3 | 3.4 | -0.03 |
Osteoarthritis | 1.1 | 1.1 | |
Osteoporosis | 0.6 | 1 | -0.67 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 2.5 | 2.6 | -0.04 |
Polycystic ovary syndrome | 0.8 | 0.9 | -0.13 |
Postural orthostatic tachycardia syndrome | 0 | 0.1 | 0 |
Premenstrual dysphoric disorder | 0.4 | 0.3 | 0.33 |
primary biliary cholangitis | 0.1 | 1.1 | -10 |
Psoriasis | 2.4 | 2.3 | 0.04 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.9 | 2 | 0.95 |
Rosacea | 1.1 | 0.4 | 1.75 |
Schizophrenia | 3.4 | 0.4 | 7.5 |
scoliosis | 0.2 | -0.2 | |
Sjögren syndrome | 1.4 | 2.1 | -0.5 |
Sleep Apnea | 0.3 | 0.6 | -1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.2 | 2.5 |
Stress / posttraumatic stress disorder | 2.1 | 1.7 | 0.24 |
Systemic Lupus Erythematosus | 2.4 | 0.5 | 3.8 |
Tic Disorder | 0.1 | 0.7 | -6 |
Tourette syndrome | 0.4 | 0.2 | 1 |
Type 1 Diabetes | 1.2 | 0.5 | 1.4 |
Type 2 Diabetes | 4.8 | 4.4 | 0.09 |
Ulcerative colitis | 1.4 | 3.3 | -1.36 |
Unhealthy Ageing | 4.1 | 1.7 | 1.41 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.